Merck and Moderna’s personalized mRNA vaccine approach in melanoma generated clinical data showing a lower risk of recurrence and death compared with standard of care. The company’s updated trial results reported a 42% reduction in the risk measure, reinforcing the personalized-vaccine strategy as a potential differentiator in adjuvant settings.